1. Home
  2. CAN vs NKTX Comparison

CAN vs NKTX Comparison

Compare CAN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.43

Market Cap

486.0M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.14

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
NKTX
Founded
2013
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.0M
132.8M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
CAN
NKTX
Price
$0.43
$2.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$3.09
$13.25
AVG Volume (30 Days)
8.9M
668.8K
Earning Date
02-10-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$63.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$1.31
52 Week High
$2.22
$2.81

Technical Indicators

Market Signals
Indicator
CAN
NKTX
Relative Strength Index (RSI) 34.50 39.72
Support Level $0.43 $1.95
Resistance Level $0.55 $2.32
Average True Range (ATR) 0.03 0.16
MACD 0.00 -0.06
Stochastic Oscillator 5.32 2.84

Price Performance

Historical Comparison
CAN
NKTX

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: